CDT Equity Advances AstraZeneca PLC (AZN)'s AZD5904 Into PCT Patent Protection Stage
TheFly reported on May 6 that CDT Equity announced that AZD5904, a selective inhibitor of human myeloperoxidase originally licensed from AstraZeneca PLC (NYSE:AZN), has entered the Patent Cooperation ...







